These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27067683)

  • 1. [Management of Stomatitis Associated with Treatment with Everolimus].
    Ota Y; Kurita H; Umeda M
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):203-9. PubMed ID: 27067683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.
    Divers J; O'Shaughnessy J
    Clin J Oncol Nurs; 2015 Aug; 19(4):468-74. PubMed ID: 26207713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
    Jones VE; McIntyre KJ; Paul D; Wilks ST; Ondreyco SM; Sedlacek S; Melnyk A; Oommen SP; Wang Y; Peck SR; O'Shaughnessy JA
    Oncologist; 2019 Sep; 24(9):1153-1158. PubMed ID: 30833486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Stomatitis: Using Dexamethasone-Based Mouthwash to Inhibit Everolimus-Related Stomatitis.
    Saigal B; Guerra L
    Clin J Oncol Nurs; 2018 Apr; 22(2):211-217. PubMed ID: 29547614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
    Rugo HS; Hortobagyi GN; Yao J; Pavel M; Ravaud A; Franz D; Ringeisen F; Gallo J; Rouyrre N; Anak O; Motzer R
    Ann Oncol; 2016 Mar; 27(3):519-25. PubMed ID: 26759276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis.
    de Lima M; Hajj G; de Lima V; Alves FA
    Oral Dis; 2018 Mar; 24(1-2):207-209. PubMed ID: 29480592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial.
    Niikura N; Ota Y; Hayashi N; Naito M; Kashiwabara K; Watanabe K; Yamashita T; Mukai H; Umeda M
    Jpn J Clin Oncol; 2016 Sep; 46(9):879-82. PubMed ID: 27365521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus.
    Kalogirou EM; Tosios KI; Piperi EP; Sklavounou A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Jan; 119(1):e13-9. PubMed ID: 25442249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy-induced stomatitis and diarrhea].
    Kadowaki S; Yamaguchi K
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1761-6. PubMed ID: 22083181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of treatment outcomes after implementation of comprehensive pharmaceutical care in breast cancer patients receiving everolimus and exemestane.
    Todo M; Ueda S; Osaki S; Sugitani I; Takahashi T; Takahashi M; Makabe H; Saeki T; Itoh Y
    Pharmazie; 2018 Feb; 73(2):110-114. PubMed ID: 29442014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa.
    Sonis S; Andreotta PW; Lyng G
    Oral Dis; 2017 Apr; 23(3):347-352. PubMed ID: 27896917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mucositis].
    Sato A; Sakashita A; Taguchi S
    Nihon Rinsho; 2003 Jun; 61(6):959-65. PubMed ID: 12806943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Everolimus in Daily Clinical Practice Focusing to Oral Mucosa Damage Issues - Single Oncology Centre Experience within the Course of the Year 2016].
    Vokurka S; Votavová M; Arnetová V; Korunková H; Svoboda T; Kulhánková J; Kališová K; Matějka VM; Fiala O; Fínek J
    Klin Onkol; 2017; 30(Supplementum1):195-197. PubMed ID: 28471205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R; Lacouture M; Wu S
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the incidence of stomatitis using a quality assessment and improvement approach.
    Graham KM; Pecoraro DA; Ventura M; Meyer CC
    Cancer Nurs; 1993 Apr; 16(2):117-22. PubMed ID: 8477399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stomatitis in mTOR inhibitors treatment and other targeted cancer therapy, possibilities of infl uencing it, and the use of local corticotherapy.
    Vokurka S; Kozáková Š; Jánská V; Černá A; Liška J
    Klin Onkol; 2020; 33(6):436-439. PubMed ID: 33685192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.
    Goldberg HJ; Harari S; Cottin V; Rosas IO; Peters E; Biswal S; Cheng Y; Khindri S; Kovarik JM; Ma S; McCormack FX; Henske EP
    Eur Respir J; 2015 Sep; 46(3):783-94. PubMed ID: 26113676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types.
    Hattori M; Hagiwara S; Kotani H; Tatematsu M; Tachi M; Hijioka S; Shimizu J; Andoh M; Mizuno Y; Sawaki M; Yoshimura A; Gondo N; Adachi Y; Yoshimura K; Iwata H
    Int J Clin Oncol; 2019 Oct; 24(10):1320-1327. PubMed ID: 31154565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.
    Peterson DE; O'Shaughnessy JA; Rugo HS; Elad S; Schubert MM; Viet CT; Campbell-Baird C; Hronek J; Seery V; Divers J; Glaspy J; Schmidt BL; Meiller TF
    Cancer Med; 2016 Aug; 5(8):1897-907. PubMed ID: 27334013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.